Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-716 adjuvant pembrolizumab versus placebo after resection of high-risk stage II melanoma
MOH_2019-03-07_006014Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab in melanoma (3 arms), sponsored by Merck & Co. Primary endpoints: Recurrence-free survival and Safety. Started Jul 2018; status: active, not recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on MOH_2019-03-07_006014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-03-07_006014.